Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
1997 2
1998 7
1999 2
2000 4
2001 1
2002 2
2003 4
2004 3
2007 1
2008 1
2010 2
2012 7
2015 2
2016 1
2017 1
2018 2
2019 4
2020 3
2021 9
2022 17
2023 24
2024 9
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 37643277

101 results

Results by year

Filters applied: . Clear all
Page 1
Tebentafusp.
[No authors listed] [No authors listed] 2023 Jul 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jul 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37643277 Free Books & Documents. Review.
Tebentafusp: First Approval.
Dhillon S. Dhillon S. Drugs. 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4. Drugs. 2022. PMID: 35364798 Review.
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, Gupta A, Vardeu A, Leach E, Naidoo R, Stanhope S, Lewis S, Hurst J, O'Kelly I, Sznol M. Middleton MR, et al. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. doi: 10.1158/1078-0432.CCR-20-1247. Epub 2020 Aug 18. Clin Cancer Res. 2020. PMID: 32816891 Free PMC article. Clinical Trial.
Tumor lysis syndrome induced by tebentafusp.
Ruf T, Leonhardt A, Anz D, Kunz WG, Röhrle N, Foerster P, Tomsitz D, French LE, Seegräber M, Heinzerling L. Ruf T, et al. Immunotherapy. 2023 Nov;15(16):1363-1368. doi: 10.2217/imt-2023-0093. Epub 2023 Sep 4. Immunotherapy. 2023. PMID: 37661909
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Nathan P, et al. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. N Engl J Med. 2021. PMID: 34551229 Free article. Clinical Trial.
101 results